Preclinical animal studies with radioiododeoxyuridine

Journal of Nuclear Medicine

Volumn 37, Issue 4 SUPPL., 1996, Pages

  Kassis, Amin I ^a,b   Adelstein, S James ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Shields Warren Radiation Laboratory   (United States)

Author keywords

Iodine 123 IUdR; Iodine 125 IUdR; Locoregional administration; Tumor therapy and diagnosis

Indexed keywords

IDOXURIDINE; RADIOACTIVE IODINE;

ANIMAL; BLADDER TUMOR; BRAIN TUMOR; EXPERIMENTAL NEOPLASM; FEMALE; GLIOSARCOMA; MOUSE; OVARY TUMOR; RAT; REVIEW;

ANIMALS; BRAIN NEOPLASMS; FEMALE; GLIOSARCOMA; IDOXURIDINE; IODINE RADIOISOTOPES; MICE; NEOPLASMS, EXPERIMENTAL; OVARIAN NEOPLASMS; RATS; URINARY BLADDER NEOPLASMS;

EID: 0030116195     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Eidinoff ML, Cheong L, Rich MA. Incorporation of unnatural pyrimidine bases into deoxyribonucleic acid of mammalian cells. Science 1959;129:1550-1551.
2. Morris NR, Cramer JW. DNA synthesis by mammalian cells inhibited in culture by 5-iodo-2′-deoxyuridine. Mol Pharmacol 1966;2:1-9.
3. 125IUdR in mammalian cells: implications of localized energy deposition by Auger processes. Radiat Res 1987;109:78-89.
4. Bresnick E, Thompson UB. Properties of deoxythymidine kinase partially purified from animal tumors. J Biol Chem 1965;240:3967-3974.
5. 125I after incorporation into the DNA of the mouse. Nature (London) 1965;206:949-950.
6. Klecker RW Jr, Jenkins JF, Kinsella TJ, Fine RL, Strong JM, Collins JM. Clinical pharmacology of 5-iodo-2′-deoxyuridine and 5-iodouracil and endogenous pyrimidine modulation. Clin Pharmacol Ther 1985;38:45-51.
7. 125I-iododeoxyuridine and azauridine. Cancer Res 1963;23:1246-1259.
8. 125I. Radiat Res 1981;87:10-23.
9. Kassis AI, Sastry KSR, Adelstein SJ. Intracellular localisation of Auger electron emitters: biophysical dosimetry. Radiat Prot Dosim 1985;13:233-236.
10. 125I in mammalian cells. Radiat Res 1987;111:305-318.
11. 125I incorporated into mammalian DNA. Proc Natl Acad Sci USA 1974;71:4836-4838.
12. 3H. Nuclear versus cytoplasmic radiation effects in murine L1210 leukemia. Int J Radiat Biol 1975;28:225-241.
13. 131I. Radiat Res 1971;47:94-109.
14. 3HTdR. Radiat Res 1976;67:332-343.
15. Warters RL, Hofer KG, Harris CR, Smith JM. Radionuclide toxicity in cultured mammalian cells: elucidation of the primary site of radiation damage. Curr Top Radiat Res Q 1977;12:389-407.
16. Sastry KSR, Rao DV. Dosimetry of low energy electrons. In: Rao DV, Chandra R, Graham MC, eds. Physics of nuclear medicine: recent advances, American Association of Physicists in Medicine, Medical Physics Monograph no. 10. Woodbury, NY: American Institute of Physics; 1984:169-208.
17. 125I]iodo-2′-deoxyuridine. Radiat Res 1989;118:532-544.
18. Makrigiorgos GM, Berman RM, Baranowska-Kortylewicz J, et al. DNA damage produced in V79 cells by DNA-incorporated iodine-123: a comparison with iodine-125. Radiat Res 1992;129:309-314.
19. 123I]iodo-2′-deoxyuridine in the radiotherapy of an early ascites tumor model. Int J Radiat Oncol Biol Phys 1991;21:1541-1551.
20. Bloomer WD, Adelstein SJ. Antineoplastic effect of iodine-125-labeled iododeoxyuridine. Int J Radiat Biol 1975;27:509-511.
21. 125I-iododeoxyuridine as prototype for radionuclide therapy with Auger emitters. Nature [London] 1977;265:620-621.
22. Van den Abbeele AD, Tutrone RF, Berman RM, et al. Tumor targeting potential of radioiodinated iododeoxyuridine in bladder cancer. J Nucl Med 1996;37:315-320.
23. 125I]iodo-2′-deoxyuridine in rat brain tumors: diagnostic and therapeutic implications in humans. Cancer Res 1990;50:5199-5203.
24. 125I]iodo-2′-deoxyuridine in the radiotherapy of solid brain tumors in rats [Abstract]. J Nucl Med 1993;34(suppl):241P.
25. 125IUdR in a rat model of meningeal carcinomatosis [Abstract]. Proc Am Assoc Cancer Res 1994;35:414.